Mathieu Rousseau

Last wk to apply! Come spend a yr with us in beautiful Montreal honing your expertise in UpperGI and Thoracic Surgery. Great opportunity with my amazing colleagues! ⁦@DoctorJSpicer⁩ @JonathanCools⁩ ⁦@sara_najmeh⁩ ⁦@LFerri123⁩ ⁦ mcgill.ca/thoracic/fello…

The VALUE Trial team shows that same-day discharge after VATS lung resection can be done safely for carefully selected patients. Strong work from @DoctorJSpicer, @MThoracics, @LyndonCWalsh, @filippog92 & @MeravRokah 👏. In LuCE’s 5th Report, 6 in 10 people said family life was heavily affected by #lungcancer - time away from loved ones adds to the challenge. 📄 Spicer et al., JTCVS 2025 🔗 sciencedirect.com/science/articl… #ThoracicSurgery #LCSM

Super proud of our team @MThoracics for putting together this trial showing that same day discharge after lung resection, specifically anatomic lung resection, is both safe and feasible! Would not have been possible without the hard work of @LyndonCWalsh and @MeravRokah, as well as our nurses Erin Cronin and Tia Wallace. @sara_najmeh is now leading our standard of care pathway implementation! sciencedirect.com/science/articl…

Come to beautiful Montreal for outstanding fellowships in both upper GI surgery and advanced thoracic surgery.

Are you a general or thoracic surgeon looking to develop your skills with a world-class team of thoracic surgeons? Less than 1mo to submit application to our fellowship program for position starting July 2026. ⁦@DoctorJSpicer⁩ ⁦@LFerri123⁩ mcgill.ca/thoracic/fello…

@DoctorJSpicer just articulated what I think has been the theme of the paradigm changing work presented at #ASCO24, “It’s more about disease biology than the anatomical extent.” This is absolutely how I am beginning to think about lung cancer—staging is not a complete prognostic indicator.

ESOPEC trial It’s been a long 15 year journey, but so nice to see Docetaxel triplets come on top for the benefit of our patients! CROSS just doesn’t work for GEA-EAC- radiation compensates for poor surgical control (trans-hiatal) and CM577 compensates for poor systemic control

🚨🚨🚨 #ESOPEC🚨🚨🚨 🔥Practice shifting trial🔥 Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma Randomized Peri-op FLOT (FLOT4) vs Pre-operative chemoradiation (CROSS) Congrats to the study investigators! Let’s dive in! #ASCO24 @MayoRadOnc 1/

@StephenVLiu @dramycummings @marinagarassino @DoctorJSpicer And an interesting question raised during the discussion. Are we still paying too much attention to stage for treatment decision as oppose to tumor biology and patient factors?

Engaging panel discussion at #ASCO24 on perioperative immunotherapy for NSCLC with Drs. Alberto Chiappori @dramycummings @marinagarassino @DoctorJSpicer John Heymach. Reported regimens more similar than different, which is reassuring.

New from the Plenary Session at #ASCO24: ESOPEC helps settle debate on superiority of perioperative #chemo (FLOT) vs neoadjuvant chemoradiotherapy (CROSS) in esophageal cancer with 29-month improvement in OS with FLOT vs CROSS: brnw.ch/21wKmPS #ASCODailyNews #esocsm

FLOT improves OS over CROSS in esophageal Adenoca ESOPEC trial, #ASCO2024 @LFerri123 @JonathanCools

«De garde 24/7» vous revient pour une 9e saison dans de tous nouveaux lieux. Découvrez les équipes de l'hôpital Sacré-Coeur de Montréal, l'hôpital Le Royer de Baie-Comeau et de l'EVAQ. 📺Jeudi 20h, dès le 7 septembre 👉youtu.be/4pi4aFDfjjo

After 4 years of preparation, finally able to provide surgical care to our Inuit patient population within their communities. Sixteen satisfied patients treated this week who did not have to travel 1600km to Montreal for their surgeries. #Puvirnituq

Protocol and human error to blame, not ‘inability’ to treat rape victim in French cultmtl.com/2023/07/protoc… via @Crunchify

36 000 ppl at @ASCO. Impressive plenary with @Surgeon_General.

That’s why I tell my patients Lung Cancer is the new Breast Cancer. ⁦@ASCO⁩ That’s where we are going too!

@esinghimd @FordePatrick @DoctorJSpicer @JackWestMD @LungCancerRx I believe we’ll learn about it for CM816 tomorrow. From the abstract: “In pts who did not receive definitive surgery, these exploratory analyses showed that neoadjuvant N + C was associated with numerically improved TTDM”

Important to consider, what happens to the 15-20% of patients on these trials who do not make it to surgery? #lcsm #ASCO23

IO: Pre-op, post-op, or both? Excellent discussion by @DrMarkAwad this morning 👏 #ASCO23 #lcsm @OncoAlert @LungCancerRx First, what we have:

@Tony_Calles Was AEGEAN screening failure rate presented at AACR? The surgical eligibility criteria were even more strict with AEGEAN. Anticipated pneumonectomy were excluded which lead to many screening failure at our site.

Is neoadjuvant Chemo-immunotherapy feasible for all your potentially operable stage II-III NSCLC patients in the clinic? In KN-671 trial, only 796/1364 patients fulfil the eligibility criteria. That’s 42% screening failure rate‼️#ASCO23 #LCSM

Amazing talk by @DrMarkAwad @ASCO Cross trials comparisons of peri-op IO. Neoadj seems advantageous. The ❔remains,what to do with poor path responders? Frequent discussion at our TB, data is badly needed. Didn’t bring up radiation as an option for persistent N2. Thoughts?